GILD Share Price

Open 73.32 Change Price %
High 74.41 1 Day 0.34 0.46
Low 73.28 1 Week 3.19 4.52
Close 73.76 1 Month 3.28 4.65
Volume 8867711 1 Year -12.79 -14.78
52 Week High 88.85
52 Week Low 63.76
GILD Important Levels
Resistance 2 74.81
Resistance 1 74.38
Pivot 73.82
Support 1 73.14
Support 2 72.71
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
ASTI 0.00 0.00%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
TEAR 3.34 89.77%
SCHS 0.05 66.67%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
TOPS 0.26 23.81%
BONT 0.80 17.65%
HAUP 0.07 16.67%
PLUG 2.44 15.09%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Gilead Sciences, Inc. (NASDAQ: GILD)

GILD Technical Analysis 4
As on 21st Jul 2017 GILD Share Price closed @ 73.76 and we RECOMMEND Buy for LONG-TERM with Stoploss of 71.62 & Strong Buy for SHORT-TERM with Stoploss of 67.49 we also expect STOCK to react on Following IMPORTANT LEVELS.
GILD Target for July
1st Target up-side 75.36
2nd Target up-side 78.58
3rd Target up-side 81.79
1st Target down-side 66.2
2nd Target down-side 62.98
3rd Target down-side 59.77
GILD Other Details
Segment EQ
Market Capital 51045679104.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.gilead.com
GILD Address
GILD
333 Lakeside Drive
Foster City, CA 94404
United States
Phone: 650-574-3000
Fax: 650-578-9264
GILD Latest News
Interactive Technical Analysis Chart Gilead Sciences, Inc. ( GILD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Gilead Sciences, Inc.
GILD Business Profile
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.